Paper Details

  1. Home
  2. Paper Details

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.

Author: ChartashElliot K, FischkoffSteven A, HuaYe, KavanaughArthur F, KeystoneEdward C, SharpJohn T, TannenbaumHyman, TeohLeah S

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the effects of adalimumab, a medication that blocks tumor necrosis factor (TNF), in patients with active rheumatoid arthritis (RA) who were also taking methotrexate (MTX). The study aimed to see if adalimumab could slow down joint damage, reduce symptoms, and improve physical function in these patients.
Paper Details　
Original Abstract of the Article :
Tumor necrosis factor (TNF) is an important proinflammatory cytokine that mediates inflammatory synovitis and articular matrix degradation in rheumatoid arthritis (RA). We investigated the ability of adalimumab, a human anti-TNF monoclonal antibody, to inhibit the progression of structural joint dam...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/art.20217

データ提供：米国国立医学図書館（NLM）

Adalimumab: A New Hope for Rheumatoid Arthritis

This study investigates the efficacy of adalimumab, a human anti-tumor necrosis factor (TNF) monoclonal antibody, in treating rheumatoid arthritis (RA) patients receiving concomitant methotrexate (MTX) therapy. The study was a randomized, placebo-controlled trial involving 52 weeks of treatment. The results demonstrated that adalimumab, in combination with MTX, significantly improved clinical and functional outcomes in patients with active RA. The study found that adalimumab effectively inhibited the progression of structural joint damage, reduced signs and symptoms, and improved physical function in RA patients.

A New Oasis in the Desert of RA Treatment

This study presents adalimumab as a promising new treatment option for rheumatoid arthritis patients, offering a potential oasis in the desert of treatment options. The study's findings demonstrate the effectiveness of adalimumab in combination with methotrexate, suggesting a significant improvement in clinical and functional outcomes for RA patients. This research is like discovering a new source of water in a parched desert, offering hope and relief for those suffering from RA.

Navigating the Challenges of Rheumatoid Arthritis

This research highlights the ongoing search for effective treatments for rheumatoid arthritis, emphasizing the need for innovative approaches and continued research. The study's findings suggest that adalimumab, in combination with methotrexate, offers a potential pathway towards improved outcomes for RA patients, providing a beacon of hope for those navigating the challenges of this debilitating condition. This research is like a guidepost in the desert of RA treatment, helping us to navigate the complexities of this condition and to discover new paths toward improved patient care.

Dr. Camel's Conclusion

This study demonstrates the efficacy of adalimumab, a human anti-TNF monoclonal antibody, in treating rheumatoid arthritis patients receiving concomitant methotrexate therapy, suggesting a significant improvement in clinical and functional outcomes for RA patients.

Date :
  1. Date Completed 2004-06-15
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

15146409

DOI: Digital Object Identifier

10.1002/art.20217

Related Literature

Article Analysis
・Effective treatment of rheumatoid arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.